PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn

a technology of peptides and igg, applied in the field of immunomodulators, can solve the problems of shortening the half-life of serum igg and not being protected from degradative mechanisms, and achieve the effect of preventing igg from recycling

Inactive Publication Date: 2011-03-10
BIOGEN HEMOPHILIA
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0044]The invention further relates to a method of regulating IgG levels in the serum of a subject comprising administering to the subject a therapeutically effective amount of a composition comprising one or more peptides of the invention capable of binding to and preventing the FcRn from binding to the Fc portion of an IgG molecule. In certain embodiments, the methods of the invention are employed to reduce the half-life of soluble IgG in the serum of a subject. The result of administering a composition of the invention is that the half-life of soluble IgG in the serum of the subject is reduced compared to the half-life of IgG in the serum of the subject prior to administration of the peptide.

Problems solved by technology

If the concentration of IgG reaches a level that exceeds available FcRn, unbound IgG will not be protected from degradative mechanisms and will consequently have a shorter serum half-life.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn
  • PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn
  • PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn

Examples

Experimental program
Comparison scheme
Effect test

example 1

Expression of Soluble Human FcRn (shFcRn)

[0286]Soluble human FcRn cDNA was cloned, expressed and purified as described in the literature using the glutamine synthetase expression system in Chinese hamster ovary (CHO) cells See U.S. Pat. No. 5,623,053. A stop codon was placed after amino acid position 274 in the protein sequence of human FcRn in order to remove the transmembrane region.

example 2

Transfection of HEK 293 Cells with Human FcRn

[0287]Human embryonic kidney (HEK) 293 cells (ATCC, Manassas, Va.) were transfected using the SuperFect Transfection Reagent (Qiagen, Valencia, Calif.) according to the manufacturer's recommended protocol. The full length FcRn cDNA construct depicted in FIG. 1 (C. M. Story et al., J. Exp. Med. 180:2377-2381 (1994), N. E. Simister et al., Eur. J. Immunol. 26:1527-1531 (1996)) was originally cloned into pcDNA6 (Invitrogen, Carlsbad, Calif.) as the plasmid vector in order to generate the FcRn expression vector, FcRn:pcDNA6. The Human □2m cDNA construct, also depicted in FIG. 1 was originally cloned into pcDNA3 (Invitrogen) as the plasmid vector to generate the human □2m expression vector, □2m:pcDNA3 (D. Gussow et. al., J. Immunol. 139:3132-3138 (1987)).

[0288]The day before transfection, HEK293 cells were seeded at 0.5-2.5×106 cells per 100 mm dish and incubated at 37° C. and 5% CO2 for 16 hours in cDMEM. The composition of cDMEM contains: 1 ...

example 3

Screening of Phage Libraries for FcRn-IgG Inhibitors

[0290]Peptides capable of inhibiting the binding of the IgG Fc portion to FcRn were identified by screening filamentous phage display libraries licensed from Dyax Corp. (Cambridge, Mass.). More specifically, the following three libraries were used in combination; TN-9-IV, TN10-X, TN-11-I and TN-12-I were used in the screen. The total number of individual viable phage contained in each library was reflected by the number of transformants established for each library when the libraries were expressed in E. coli and plated at a clonal dilution as described by the Dyax protocol. The number of transformants for TN-9-IV, TN10-X, TN-11-I and TN-12-I was 3.2×109, 2×109, 2.7×109 and 1.4×109, respectively. Another way to refer to the absolute number of viable phages in a given volume is by stating the plaque forming units (pfu) per unit volume.

[0291]A. Buffers Used in Phage Screening

[0292]The following buffers were used for the screening of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
hydrophobicaaaaaaaaaa
structureaaaaaaaaaa
Login to view more

Abstract

The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.

Description

PRIOR APPLICATIONS[0001]This application claims priority to U.S. Provisional Application Nos. 60 / 774,853, filed Feb. 17, 2006, and 60 / 805,634, filed Jun. 23, 2006, the contents of which are hereby incorporated by reference in their entirety.FIELD OF THE INVENTION[0002]The invention generally relates to the field of immuno-modulators. More specifically, the invention relates to peptides which bind to the Fc neonatal Receptor (FcRn) and inhibit binding of the FcRn to a Fc portion of an immunoglobulin G (IgG), thereby modulating serum IgG levels. The invention further relates to peptide modulators of FcRn activity that can prevent FcRn from functioning in cellular mechanisms related to the maintenance of IgG levels in the serum, medicaments comprising those peptides, and methods of treating a subject for diseases and disorders that can be alleviated by lowering serum IgG levels by administering those medicaments.BACKGROUND OF THE INVENTION[0003]The most abundant antibody isotype in the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/12C07K7/64C07K14/00C07K14/79C07K7/52C07K14/76C07K19/00A61K38/16A61P35/00A61P3/10A61P17/06A61P1/04A61P29/00C07K1/22A61P37/06G01N33/53
CPCA61K38/00C07K7/06C07K7/08G01N2333/70535C07K14/70535C07K14/70539C07K14/00A61P1/00A61P1/04A61P1/16A61P11/06A61P13/12A61P17/00A61P17/02A61P17/04A61P17/06A61P19/02A61P21/00A61P21/04A61P25/00A61P29/00A61P35/00A61P37/02A61P37/04A61P37/06A61P37/08A61P43/00A61P7/02A61P7/06A61P7/10A61P9/10A61P3/10C07K14/435
Inventor MEZO, ADAM R.MCDONNELL, KEVIN A.TAN HEHIR, CRISTINA A.CASTRO, ALFREDO
Owner BIOGEN HEMOPHILIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap